Introduction
Increasing evidence has indicated that cellular redox status modulates aspects of various cellular events, including proliferation and apoptosis (Finkel, 2003) . Thioredoxin (Trx) is a cellular redox enzyme that plays multiple roles in these redox-dependent cellular events (Holmgren, 1985 (Holmgren, , 1989 Powis et al., 2000) by catalysing thiol-disulfide exchange reactions through reversible oxidation of its active center dithiol (Cys32 and Cys35) to disulfide (Yodoi et al., 2001) . Several transcription factors are post-translationally altered by such redox modification(s) of specific cysteine residue(s). Trx facilitates the transcriptional activities of nuclear factor (NF)-kB and the glucocorticoid receptor via direct associations with their DNA-binding domains (Matthews et al., 1992; Hayashi et al., 1993; Qin et al., 1995; Makino et al., 1999) . In addition, Trx enhances the DNA-binding activity of the activator protein 1 (AP-1) transcription factor through an activation cascade beginning with Trx, proceeding to another regulatory protein, redox factor-1 (Ref-1), and subsequently continuing to AP-1 through direct cysteinemediated associations and reduction processes (Xanthoudakis and Curran, 1992; Xanthoudakis et al., 1994; Hirota et al., 1997) . Recently, Trx was isolated as a binding protein of the mitogen-activated protein (MAP) kinase kinase kinase, apoptosis signal-regulating kinase 1 (ASK1). Binding of Trx inactivates ASK1 catalytic activity. Under conditions of oxidative stress, oxidation of the Trx dithiol induces dissociation of the Trx-ASK1 complex, resulting in ASK1 activation and downstream MAP kinase signaling (Saitoh et al., 1998) . Trx was also suggested to be a major electron donor for the reduction of protein-tyrosine phosphatase 1B, which was reversibly oxidized and inactivated following treatment of A431 cells with epidermal growth factor (Lee et al., 1998) . In addition to the above examples, a variety of proteins are expected to be under the regulation of cellular redox status through direct interactions with Trx. Thus, the findings of new Trx-interacting proteins will be very helpful to understand redox-dependent cellular events.
Jun activation domain-binding protein 1 (Jab1), initially identified as a coactivator of AP-1 (Claret et al., 1996) , is the fifth component (CSN5) of the COP9 signalosome (CSN) complex (Seeger et al., 1998; Wei et al., 1998; Deng et al., 2000) . Jab1/CSN5 interacts with a variety of proteins and controls their functions; it plays roles in diverse cell signaling pathways, including regulation of gene transcription and cell cycle via phosphorylation, and degradation of target proteins (Chamovitz and Segal, 2001) . Interaction of Jab1 with c-Jun enhances binding of c-Jun-containing AP-1 complexes to their DNA consensus sites and increases AP-1-dependent transcription, thus leading to cell proliferation (Claret et al., 1996) . Jab1 was also identified as a direct negative regulator of the CDK inhibitor, p27Kip1, resulting in cell cycle progression (Tomoda et al., 1999) . Interaction of Jab1 with the tumor suppressor p53 induces CSN-mediated phosphorylation and subsequent degradation of p53 (Bech-Otschir et al., 2001) . Jab1 also interacts with hypoxia-inducible factor1a (HIF-1a) and enhances its stability, leading to increased expression of vascular endothelial growth factor, a major HIF-1a target, under hypoxic conditions (Bae et al., 2002) . Taken together, these observations suggest that Jab1 may play an important role in human oncogenesis. Interestingly, overexpression of Jab1 has been correlated with aggressiveness or inferior overall survival in human pituitary tumors (Korbonits et al., 2002) , epithelial ovarian cancer (Sui et al., 2001) , breast cancer (Kouvaraki et al., 2003) , and some types of lymphoma (Ito et al., 2003; Rassidakis et al., 2003) . These findings suggest that the increased malignancy may be due to pleiotropic phenotypes resulting from Jab1 overexpression, such as decreased levels of p27, upregulation of AP-1 transcriptional activity, and CSNmediated phosphorylation of various transcription regulators. Thus, control of Jab1 may be a likely new target for experimental therapies.
In the present study, we sought to identify Trxinteracting proteins with a yeast two-hybrid strategy. We used an active site mutant (Cys35Ser) of Trx as bait, since this mutant was capable of enhancing the reporter signal in the yeast two-hybrid system by trapping the thiol-disulfide exchange intermediate between Trx and the target protein (Holmgren, 1985) . Our work identifies a new role of Trx in regulating Jab1 function, leading to the modulation of AP-1 activation and p27Kip1 degradation. Based on this, we propose that Trx may have potential as a novel cancer therapeutic strategy.
Results

Trx interacts with Jab1 in vitro and in vivo
We used a full-length cDNA of mutant Trx Cys35Ser, in which Cys35 was replaced by Ser, fused to the DNAbinding domain of LexA as bait in a yeast two-hybrid assay, and screened approximately 5 Â 10 6 clones from a human brain cDNA library. In total, 38 types of clones interacted specifically when tested for nutritional selection and b-galactosidase activity. Four of these clones were identified as members of the peroxiredoxin protein family. These are well-known Trx-interacting proteins, thus their identification confirmed that the two-hybrid system worked properly. Of the other identified clones, one contained a cDNA insert with half of the coding sequence (amino acids 175-334) of the human Jab1. Further analyses were directed toward Jab1 because of its involvement in AP-1 activation and p27Kip1 degradation. The full-length cDNA of Jab1 was constructed by PCR from the human brain cDNA library and was used for further analysis.
To verify a specific interaction between Trx and Jab1, we performed pull-down and co-immunoprecipitation experiments. First, we observed in vitro binding of purified recombinant Jab1 with recombinant glutathione-S-transferase (GST)-tagged Trx; the GSTtagged trapping mutant Trx Cys35Ser showed a stronger binding than the GST-tagged wild-type Trx, while GST alone showed no binding ( Figure 1a) . Thus, we could confirm that the Cys35Ser Trx would be useful for screening of binding partners for wild-type Trx, and used wild-type Trx instead of Cys35Ser Trx in the subsequent experiments. We also observed in vivo complex formation when Flag-tagged Jab1 and GST-tagged wild-type Trx were coexpressed in human embryonic kidney (HEK) 293T cells. Flag-Jab1 bound to GST-Trx, but not to GST alone ( Figure 1b) . Furthermore, we investigated the in vivo interaction of the endogenous partners expressed at normal levels. Endogenous Jab1-Trx complexes were precipitated from untreated HeLa cells. Specific coprecipitation of Trx was detected by Western blot analysis with anti-Trx antibody when anti-Jab1 antibody, but not the control antibody, was used for immunoprecipitation ( Figure 1c) . In reverse order, specific coprecipitation of Jab1 was detected by anti-Jab1 Western blot when anti-Trx antibody, but not the control antibody, was used for immunoprecipitation ( Figure 1d) . Together, the results of these protein-protein interaction assays and the yeast two-hybrid screen indicate that Trx specifically binds to Jab1, suggesting that we have identified a novel interaction between Trx and Jab1.
To further investigate the region at which Jab1 binds to Trx, we constructed truncated versions of Jab1 on the basis of domain structure. Jab1 reportedly has an MPN domain (amino acids 55-165), a nuclear export signal (NES) domain (amino acids 233-242), and a coiled-coil domain (amino acids 253-282). Thus, we dissect Jab1 into N-terminal Jab1(N), containing amino acids 1-180, and C-terminal Jab1(C), containing amino acids 175-334. We successfully expressed Jab1(N) in mammalian cells but were unable to express Jab1(C). Thus, we expressed and purified recombinant Jab1(N), Jab1(C), and full-length Jab1 in Escherichia coli, incubated these Jab1 proteins with Trx-immobilized Affi-Gel 15 beads, and analysed the binding of the various Jab1 proteins by precipitation and immunoblotting. We found that fulllength Jab1 and Jab1(C) bound to the Trx-immobilized beads, but Jab1(N) did not (Figure 1e ). Consistent with these observations, an in vivo co-immunoprecipitation experiment using Jab1(N) ectopically expressed in HEK 293 T cells showed no evidence of Jab1(N) binding to Trx (data not shown). Together, these data indicate that unlike p27Kip1, which has been known to interact with the N-terminal region of Jab1 (Tomoda et al., 2002) , Trx specifically interacts with the C-terminal region of Jab1.
Jab1 and Trx colocalize and exhibit FRET in vivo
To test whether Trx and Jab1 proteins colocalize in intact cells, we utilized fluorescence resonance energy transfer (FRET) technology, which is widely used to demonstrate protein-protein interactions in living cells (Truong and Ikura, 2001 ). The proteins were expressed as C-terminal fusions with two variants of enhanced green fluorescent protein (CFP and YFP, respectively) for FRET determination. In an acceptor bleach experiment, YFP and CFP signals are visualized before and after YFP has been bleached in a region of interest. If CFP and YFP are in close proximity, the donor (CFP) fluorescence should increase in the region where the acceptor (YFP) has been bleached (Karpova et al., 2003) . Transfected alone (data not shown) or together (Figure 2a ), both YFP-Jab1 and CFP-Trx were distributed throughout the cell nuclei and the cytoplasm. In our overexpression system, Trx was detected at slightly higher levels in nuclei than in the cytoplasm, whereas Jab1 appeared primarily in the cytoplasm (Figure 2a , upper panels) as shown previously (Caballero et al., 2002; Li et al., 2000) . After photobleaching of the acceptor fluorophore (YFP-Jab1), which led to an almost complete removal of pseudocolored fluorescence intensity ( Recombinant S-tagged Jab1 proteins purified from E. coli lysates were incubated with immobilized GST, GST-Trx (wild type), or GST-Trx (Cys35Ser) fusion proteins. Bound Jab1 proteins were detected with HRP-conjugated S-protein (Novagen), which specifically interacts with the S-tag. One-tenth of the input was loaded and probed with anti-GST antibody and S-protein for normalization. (b) HEK 293T cells were cotransfected with Flag-tagged Jab1 and either GST-tagged wild-type TRX or empty GST vector. Co-precipitation assays were performed using GSH agarose, and the complexes were detected by immunoblotting with anti-Flag antibody. The expression levels of the Flag-or GST fusion proteins in total cell lysates (TCL) were also detected, as indicated in the lower panels. (c, d) Endogenous Trx-Jab1 complexes were immunoprecipitated from HeLa cell lysates with anti-Jab1 (c) or antiTrx antibodies (d), and the complexes were detected by immunoblotting using anti-Trx or anti-Jab1 antibodies, respectively. The two blots were also probed with the precipitating antibody (lower panels), and precipitation with preimmune serum served as a control. (e) S-tagged full-length Jab1, truncated Jab1(N), and Jab1(C) proteins were incubated with Trx-immobilized Affi-Gel 15 beads. Bound Jab1 proteins were detected with HRP-conjugated Sprotein. Blots were developed with a chemiluminescence detection system expressing both proteins were analysed and consistently produced a positive FRET result. Quantitative analysis revealed that the level of YFP fluorescence was decreased by about 81% after bleaching, whereas the level of CFP fluorescence increased about 21% (Figure 2b ). This result indicates that the two proteins were in very close proximity to each other in both the nucleus and cytoplasm, perhaps within the same protein complex, as FRET occurs only within 100 Å in case of CFP and YFP donor and acceptor pairs (Patterson et al., 2000) .
Regulation of AP-1 activity by the interaction of Trx with Jab1
The transcriptional coactivator function of Jab1 is associated with the enhancement of AP-1 transcriptional activity (Claret et al., 1996) . To investigate the physiological role of the newly observed Trx-Jab1 interaction, we determined whether Trx could modulate Jab1-enhanced AP-1 activity (Figure 3 ). Ectopic expression of Jab1 alone caused an approximately twofold increase in the level of AP-1-dependent reporter gene activity. This Jab1-enhanced AP-1 activity was decreased in a concentration-dependent manner by coexpression of Trx (Figure 3a) , suggesting that Trx is a negative regulator of Jab1 function. In addition, overexpression of Trx alone resulted in partial decrease of AP-1 activity, presumably through the negative regulation of endogenous Jab1.
To determine whether the negative effect of Trx on AP-1 activity depends on Jab1, we examined the effect of Trx overexpression on AP-1 activity when Jab1 expression was suppressed. Transfection of Jab1 antisense constructs (AS-Jab1) resulted in an obvious reduction of endogenous Jab1 levels (Figure 3b , right) and led to partial inhibition of AP-1 reporter gene activity (Figure 3b , left). However, coexpression of Trx with AS-Jab1 resulted in a significant increase in AP-1 activity (Figure 3b) , showing an inverse relationship to the negative effect of Trx on Jab1-enhanced AP-1 activity (Figure 3a ). This indicates that Trx modulates AP-1 activity in a Jab1-dependent manner. We suggest that Trx negatively regulates the AP-1 activity enhanced by Jab1 overexpression, probably through a direct interaction between Trx and Jab1, but potentiates AP-1 activity when Jab1 levels are suppressed. This stimulatory effect of Trx on AP-1 activity had been reported previously; wherein the positive regulation was not caused by direct interaction between Trx and AP-1, but caused by stepwise interaction from Trx to Ref-1 to AP-1 (Xanthoudakis and Curran, 1992; Xanthoudakis et al., 1994; Hirota et al., 1997) or de novo transcription of AP-1 subunits (Schenk et al., 1994) . However, our result provides the first evidence that Trx can negatively regulate AP-1 activity, and that this occurs through Jab1-mediated AP-1 activation signaling.
Trx inhibits Jab1-mediated degradation of p27Kip1
To investigate whether Trx could also negatively regulate another function of Jab1, we next examined the effect of Trx on the cell cycle inhibitor p27Kip1, degradation of which is initiated by binding to Jab1 (Tomoda et al., 1999) . While exogenously expressed p27Kip1 was downregulated by Jab1 coexpression (Figure 4a, lane 2) , addition of Trx reversed the Jab1-induced decrease of p27Kip1 levels, as indicated by immunoblot analysis (Figure 4a, lane 4) . However, Trx did not elevate p27Kip1 levels in the absence of Jab1 overexpression (Figure 4a , lane 3 vs lane 1). We therefore suggest that Trx inhibits overexpressed Jab1-induced p27Kip1 degradation, probably through a direct interaction between Trx and Jab1.
As Trx was shown to inhibit Jab1-dependent degradation of p27Kip1, and Jab1 is known to partially overcome p27Kip1-mediated arrest in the G 1 phase of the cell cycle (Tomoda et al., 1999) , we further explored the functional consequences of Trx on Jab1-mediated cell cycle progression in HEK 293T cells. Consistently, Figure 3 Jab1-dependent regulation of AP-1 activity by Trx. (a) Trx inhibits Jab1-mediated activation of AP-1 reporter gene activity. HEK 293T cells were transiently cotransfected with 1 mg of pCI-Jab1, different amounts (0, 1, or 2 mg) of plasmid encoding wild-type Trx, and the AP-1-driven-luciferase reporter. The total amount of transfected DNA was standardized by addition of empty vector. To determine the AP-1 reporter gene activity, cells were lysed 40 h post-transfection and luciferase activities were assayed. Left, normalized luciferase activity is represented as compared to the mock-transfected control. Right, levels of Jab1 and Trx expressions were confirmed by immunoblotting with antiJab1 and anti-Trx antibodies, respectively. b-Actin immunoblots served as a control. (b) Effect of Trx expression on AP-1 activity in Jab1-depleted cells. Cells were transiently transfected with AS-Jab1 (1 mg) and/or the wild-type Trx expression plasmid (2 mg) together with the AP-1-luciferase reporter, as indicated. AP-1 reporter gene activities were determined at 40 h after transfection. Left, foldinductions relative to the mock-transfected control are represented as the mean7s.d. of three independent experiments. Right, reduced level of endogenous Jab1 by antisense construct and overexpression of Trx were analysed by immunoblotting with anti-Jab1 and antiTrx antibodies cells transiently transfected with p27Kip1 showed a 23% increase of G 0 /G 1 phase cells, as compared with control cells. Conversely, coexpression of Jab1 with p27Kip1 significantly reduced the percentage of cells attenuated in G 0 /G 1 phase to that of mock-transfected control cells (Figure 4b) . Further, overexpression of Trx partially but significantly suppressed Jab1-mediated reduction of G 0 / G 1 phase cells, resulting in a 12% increase of the G 0 /G 1 population, as compared with cells transfected with Jab1 alone (Figure 4b , fifth bar vs third bar). These results indicate that Trx can also be a negative regulator of Jab1-mediated cell cycle progression.
p27Kip1 and Trx compete for Jab1 binding
Since p27Kip1 and Trx interact with the N-and Cterminal regions of Jab1, respectively, we examined whether Trx might influence the binding of p27Kip1 to Jab1. Ectopic expression of Trx led to decreased binding of p27Kip1 to Jab1 (Figure 5a, top panel) , accompanied by increased binding of Trx to Jab1 (Figure 5a , second panel), even though the total amount of p27Kip1 was slightly increased (Figure 5a, bottom panel) . Therefore, it is likely that Trx competes with p27Kip1 for binding to Jab1; this may be how Trx inhibits the Jab1-mediated degradation of p27Kip1 (Figure 4a ). To further examine this competition, we performed an in vitro competition assay by precipitating Jab1-p27Kip1 immunocomplexes from cell lysates coexpressing Jab1 and p27Kip1 and incubating them with various concentrations of purified recombinant Trx proteins. As the amount of added Trx increased, the Jab1-bound fraction of p27Kip1 decreased ( Figure 5b , upper panel) and the unbound fraction of p27Kip1 increased (Figure 5b , lower panel) in a dose-dependent manner. This observation confirmed the above in vivo competition results between p27Kip1 and Trx. It is interesting to speculate how two molecules that bind in nonoverlapping regions of Jab1 might compete. One possible explanation is that Trx binding induces a conformational change in Jab1, lowering the binding affinity of Jab1 for p27Kip1 and resulting in their dissociation. This dissociation may relieve p27Kip1 from Jab1-mediated degradation, which rearrest cell cycle. After 36 h, cell lysates were immunoprecipitated with anti-Flag agarose, and co-precipitated HA-p27Kip1 and GST-Trx (wild type) was detected by immunoblotting with anti-HA and anti-GST antibodies. The blot was also probed with the precipitating antibody for normalization. The expression levels of GST, GSTTrx, and p27Kip1 in total cell lysates were also visualized by immunoblotting. (b) The p27Kip1-Jab1 complex was immunoprecipitated with anti-Flag agarose from cell lysates coexpressing HAp27Kip1 and Flag-Jab1. The immobilized p27Kip1-Jab1 complex was incubated in the absence or presence of increasing amount of purified recombinant Trx. After reprecipitation, the amount of p27Kip1 bound in the complex or released into the buffer was analysed by SDS-PAGE followed by immunoblotting Taken together, our results show that Trx physically interacts with Jab1 to antagonize Jab1-controlled signaling pathways, including activating AP-1 transcription and degrading the CDK inhibitor, p27Kip1.
Discussion
Trx is a cellular redox enzyme that plays multiple roles in the regulation of cell growth, apoptosis, and activation (Powis et al., 2000) . In an attempt to further elucidate this redox signaling network, we searched for novel Trx-interacting proteins using a yeast two-hybrid strategy. Of the successfully identified novel binding partners, we selected Jab1 for further study. We confirmed that Trx physically interacts with Jab1 in vitro and in vivo, and demonstrated that this interaction contributes to the downregulation of Jab1 functions, such as Jab1-induced AP-1 activation and Jab1-dependent p27Kip1 degradation. In a similar manner, the redox enzyme macrophage migration inhibitory factor (MIF) (Kleemann et al., 1999) , which was originally identified as a cytokine having anti-inflammatory growth-inhibitory activities, has been shown to bind to Jab1 and broadly act to negatively regulate Jab1-controlled pathways (Kleemann et al., 2000) . Considering that MIF and Trx are both redox enzymes containing Cys-X-X-Cys motif at their active sites, the regulation of Jab1 functions by both Trx and MIF may be associated with their redox activities.
Based on this, it is interesting to speculate whether other redox enzymes containing conserved Cys-X-X-Cys motifs can modulate Jab1 signaling in the same manner. In preliminary experiments, we observed that the Cys-X-X-Cys motif-containing redox enzyme glutaredoxin showed negative effects on Jab1-mediated AP-1 activation in a manner similar to that of Trx (Hwang CY and Kwon K-S, unpublished data). This is contrasted by hepatopoietin, a Cys-X-X-Cys motif-containing thiol oxidoreductase that functions in disulfide formation within glutaredoxin or thioredoxin (Senkevich et al., 2000) , which was found to potentiate Jab1-mediated AP-1 activation (Lu et al., 2002; Chen et al., 2003) . Even though it is still unclear how the redox activities of these proteins regulate Jab1-mediated cellular signaling, we speculate that the reducing capability of Trx, Grx, or MIF may inhibit Jab1, whereas the oxidizing capability of hepatopoietin may exert a positive effect on Jab1 signaling. The precise mechanism of the redox-dependent regulation of Jab1 functions is worthy of further investigation.
Of note, Trx downregulates AP-1 activity when Jab1 levels are elevated, although this does not occur when Jab1 levels are suppressed (Figure 3 ). Very recently, elevated Jab1 expression was reported in human pituitary tumors (Korbonits et al., 2002) , epithelial ovarian cancer (Sui et al., 2001) , breast cancer (Kouvaraki et al., 2003) , and some types of lymphoma (Ito et al., 2003; Rassidakis et al., 2003) . In these cases, the Jab1 levels were inversely associated with p27Kip1 levels and positively correlated with disease progression. Thus, Jab1 levels are thought to be a novel indicator of aggressiveness and high-grade tumor behavior, implying that control of Jab1 could be a novel target for the development of new tumor therapies. Based on this, we speculate that Trx, as a negative regulator of Jab1 signaling, could modulate the progression of tumors showing high-level Jab1 expression.
Materials and methods
Yeast two-hybrid screening
The MATCHMAKER LexA two-hybrid system (Clontech) was used according to the manufacturer's protocol. The coding region of human Trx (Cys35Ser) was fused in-frame to the LexA DNA-binding domain using the pLexA vector. The resulting bait plasmid was used to screen a human brain MATCHMAKER cDNA library (Clontech) constructed in the pB42AD vector to generate fusion products with heterologous 88-residue acidic activation domain. Autoactivation by Trx was not detected. Yeast transfectants were selected on Trp À Leu À His À medium and the positive colonies were tested for b-galactosidase activity.
Plasmids
The entire coding sequences of the human Jab1 and p27Kip1 cDNAs were PCR isolated from the human brain cDNA library and sequenced to confirm sequence integrity. The Jab1 cDNA was inserted into pET30b (Novagen) for the production of S-tagged Jab1 protein in E. coli; and into the pCI-neo (Promega), pFlag-CMV2 (Sigma), and pEYFP-C1 (Clontech) vectors for mammalian cell transfection experiments. cDNA fragments corresponding to amino-acid residues 1-180 and 175-334 of human Jab1 were amplified by PCR and were inserted into pET30b (Novagen) for the production of recombinant proteins, Jab1(N) and Jab1(C), respectively. The p27Kip1 cDNA was fused to a hemagglutin epitope tag at the 3 0 end of the open reading frame and inserted into pcDNA3 (Invitrogen) for mammalian expression. We generated an antisense Jab1-expressing vector by cloning a reverseorientated Jab1 cDNA into the pCI-neo vector. The 5 0 primer contained a BamHI site and 29 bases annealing to the sequence surrounding the start codon of Jab1 (5 0 -CTC TGG ATC CGA ATG GCG GCG TCC GGG AGC-3 0 ). The 3 0 primer contained an XhoI site and 36 bases annealing to the 3 0 end of the Jab1 coding sequence (5 0 -GAG CTC GAG TTA AGA GAT GTT AAT TTG ATT AAA CAG -3 0 ). The PCRamplified fragment was cloned into pGEM-T Easy vector (Promega). The EcoRI-XhoI fragment from pGEM-T-Jab1 was isolated and subcloned into the XhoI-EcoRI site of the pCI-neo plasmid, resulting in pCIASJab1. The inverse orientation of the insert was verified by sequencing. The Trx cDNA was inserted into pGEX4T-1 (Amersham Biosciences) and pET28a to construct an E. coli expression vector for the production of a GST-Trx fusion protein and 6XHis-tagged Trx protein, respectively. The mammalian version of GST-Trx was constructed by insertion of the Trx cDNA into the pEBG vector (Junn et al., 2000) . CFP-Trx fusion construct was prepared by cloning Trx cDNA into pECFP-C1 vector (Clontech). pCDSR-Trx, a mammalian vector for expression of untagged Trx, was kindly provided by Dr J Yodoi (Kyoto University, Japan). The Trx mutants were generated by substituting a Ser at Cys32 and/or Cys35 using the Quik-Change mutagenesis kit (Stratagene), according to the manufacturer's recommendations.
Protein purification and in vitro pull-down assay
Recombinant S-tagged full-length Jab1 and truncated Jab1(C) proteins were expressed in E. coli and purified by an inclusion body refolding method. Briefly, the inclusion body fraction was solubilized in 8 M urea and dialysed against a buffer containing 20 mM Tris (pH 8.0), 150 mM NaCl, 1 mM EDTA, 0.1 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride hydrochloride (AEBSF), 2 mg/ml leupeptin, and 5 mg/ml aprotinin. The dialysate containing refolded proteins was applied to Ni 2 þ affinity resin (Novagen) to increase homogeneity. Recombinant Jab1(N) protein was expressed soluble and purified with Ni 2 þ affinity resin (Novagen) following the manufacturer's recommendation. The purities of the resulting Jab1 preparations as assessed by SDS-polyacrylamide gel electrophoresis (PAGE) were >90%. Recombinant Trx was expressed in E. coli, cell lysates were precipitated with 1% streptomycin sulfate to remove nucleic acids and the supernatant was heated at 601C for 30 min. Nonprecipitated proteins containing Trx were precipitated with 90% ammonium sulfate, dialysed and subjected to the Sephacryl S-200 (Amersham Biosciences) gel filtration column chromatography. The pooled Trx fraction was dialysed and subjected to the Mono Q (Amersham Biosciences) ion-exchange column chromatography. The purified Trx was fully reduced by the addition of 10 mM DTT, dialysed against N 2 -infused buffer and stored at À801C before use. For the preparation of immobilized GST fusion proteins, E. coli lysates expressing the appropriate vectors were incubated with glutathione-immobilized agarose (Pierce) and washed with phosphate-buffered saline (PBS) containing 1% Triton X-100. The intactness of the bound GST fusion proteins was confirmed by SDS-PAGE resolution followed by Western blotting with anti-GST antibody (Amersham Biosciences). For the pull-down assay, the recombinant Stagged Jab1 proteins were incubated with GSH-agarose immobilized with GST or GST-Trx fusion protein, or Trximmobilized Affi-Gel 15 (BioRad) beads. Beads were washed, the bound proteins were recovered by boiling in SDS-PAGE sample buffer and separated by SDS-PAGE, and the resulting separated proteins were transferred to a nitrocellulose membrane. Blots were probed for S-tagged Jab1 by incubation with horseradish peroxidase (HRP)-conjugated S-protein (Novagen) followed by development with a chemiluminescence detection system (Pierce).
Co-immunoprecipitation assay
HEK 293 T and HeLa cells were maintained in Dulbecco's modified Eagle's medium (Life Technologies) supplemented with 10% fetal bovine serum, antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin), 3.7 mg/ml sodium bicarbonate, and 20 mM HEPES in a 5% CO 2 atmosphere at 371C. HEK 293T cells were plated in 60-mm dishes and calcium phosphate transfected with equal amounts of DNA (3 mg) containing different combinations of pCI-Jab1, GST-Trx, and/or empty vector. At 36 h after transfection, cells were placed on ice and washed twice with ice-cold PBS. Samples were then lysed in 600 ml of cold lysis buffer containing 20 mM HEPES (pH 7.2), 50 mM NaCl, 0.5% Triton X-100, 0.1 mM Na 3 VO 4 , 1 mM NaF, 1 mM AEBSF, 2 mg/ml leupeptin, and 5 mg/ml aprotinin. The lysates were incubated with glutathione agarose beads for 2 h at 41C, washed three times with lysis buffer, resuspended in SDS-PAGE sample buffer and analyzed by SDS-PAGE. Western blot analyses were performed with anti-Flag and anti-GST antibodies. Co-immunoprecipitation of endogenous Jab1 with endogenous Trx was analysed in lysates of untreated HeLa cells. Cell lysates were incubated with either mouse polyclonal anti-Jab1 antiserum, rabbit polyclonal anti-Trx antiserum, or control preimmune serum at 41C for 2 h. Protein A/G-Sepharose beads (Amersham Biosciences) were added to the reaction for another 2 h of incubation, then bound proteins were visualized by sequential Western blotting with antiJab1 and anti-Trx antibodies. The antibodies against Jab1 and Trx were raised against recombinant proteins purified from E. coli.
FRET Microscopy
FRET was measured by the acceptor photobleaching method using CFP-Trx and YFP-Jab1 fusion proteins as donors and acceptors, respectively. This method measures release of donor quenching after acceptor photobleaching, thus providing a measurement of close colocalization between the two fusion proteins. HEK 293 T cells were transfected with CFP-Trx and YFP-Jab1 expression plasmids, and cells on coverslips were fixed with 4% paraformaldehyde for 10 min and washed three times in PBS. The coverslips were mounted on slides in a drop of mounting medium (BIOMEDA), sealed with nail polish, and examined under a Zeiss LSM510 confocal microscope (Carl Zeiss Inc.) with a 40 mW argon laser. CFP was excited with a 458 nm argon laser at 13% power, and emission was detected through a 470-500 nm band pass filter. YFP was excited with a 514 nm argon laser at 12% power, and emission was detected after passage through a 530 nm long-pass filter. Photobleaching of the acceptor YFP was performed with a 514 nm laser at 100% power for 100 iterations on each region of interest, after which the CFP and YFP images were collected. Images were acquired at 512 Â 512 resolution at an eight-bit pixel depth in a 1.0 mm optical section, and converted to a pseudocolor scale for better visualization of changes in fluorescence intensity.
Reporter gene assay
To assay AP-1 activity, cells were calcium phosphate transfected with an AP-1-driven luciferase reporter gene and a CMV-b-gal plasmid, together with the indicated test plasmids. Cells were lysed at 40 h post-transfection and assayed for luciferase activity by a reporter gene assay kit (Promega) according to the manufacturer's instructions. Luciferase activity was normalized against the b-galactosidase activity, as determined colorimetrically with o-nitrophenyl-b-D-galactopyranoside as a substrate.
Cell cycle analysis
HEK 293 T cells were transiently transfected with various expression plasmids as indicated. At 44 h after transfection, cells were trypsinized, collected by centrifugation, washed twice with PBS, and fixed in 70% ethanol at À201C. After 24 h, the cells were collected by centrifugation and resuspended in PBS. After pretreatment with 100 mg/ml Dnase-free RNase A, cells were stained with 50 mg/ml propidium iodide for 30 min in the dark. Stained cells were dispersed with a syringe and analysed with a FACSCalibur flow cytometer (BD Biosciences). A total of 10 000 cells were analysed per sample. Dr JS Lim for FACS analysis, HA Hwang and EH Ryu for technical support, and Korea Basic Science Institute for confocal microscopy. This work was supported by Grants
